Live From WCLC 2024: Meeting Summary

Podcast | English | 2024 | 40 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research. Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA
Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA

Podcast Guests:

Hidehito Horinouchi, MD, PhD, Assistant Chief of the Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
Noemí Reguart, MD, PhD, Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain
Jacob Sands, MD, Assistant Professor of Medicine, Harvard Medical School, Lowe Cancer Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, MA, USA